ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1530

Plasma Cell Analysis As a Biomarker for Disease Activity in Patients with Granulomatosis with Polyangiitis

Bimba F. Hoyer1, Adriano Taddeo2, Maika Rothkegel2, Gerd Burmester3, Andreas H. Radbruch2 and Falk Hiepe4, 1Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, 2Deutsches Rheumaforschungszentrum, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, 4Med. Klinik m. Sp. Rheumatologie und klin. Immunologie, Charité University Hospital Berlin, Berlin, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells, biomarkers and plasma cells, Wegener's granulomatosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: B cells are thought to play an important role in granulomatosis with polyangiitis (GPA) due to the presence of autoantibodies reacting with specific neutrophil granular enzymes  (ANCA) in a vast majority of patients as well as the success of B cell depleting therapies in GPA.  Renal manifestations in GPA are considered to be directly ANCA –mediated (Flak, RJ, 2002) whereas the granulomatous inflammation appears to be mediated by CD4 T cells.

 Onto better understand the possible role of B cells in ANCA-associated vasculitis we analyzed the B cell subsets in the peripheral blood of patients with GPA and found marked changes correlating with disease activity as measured by the BVAS (Birmingham vasculitis activity score) as well as ANCA-levels. 

Methods: 14 patients with GPA (7 with active disease, 7 with inactive disease) were analyzed by flow cytometry as compared to 17 healthy donors. Staining for CD27, Cd20, CD19, MHCII, CD3, 4 and 8 was analyzed using flowjo software. Statistical analysis was performed using graph pad prism, and p-values of < 0,05 were considered as significant. The ethics committee of the Charité approved the study, and all patients had signed informed consent.

Results: Marked differences (p=0,0018) could be observed in plasma cell counts as well as frequencies in GPA patients (6,4 ±5,06/µl) with a BVAS-score > 0 as compared to those with a BVAS-score =0 (2,52± 1,6/µl) or healthy persons (2,27±1,15/µl). Plasma cell numbers as well as the frequency of plasma cells within all B cells correlated with the BVAS (r= 0,9135, p<0,0001) as well as the ANCA-level in the serum (r= 0,8316, p=0,0013). No significant differences could be observed for naive and memory B cells or the overall B cell numbers as compared to healthy donors.

Regarding T cells, there was a significant reduction of CD3 (p=0,01) and CD4 T (p=0,012) cells in patients with active GPA as compared to patients in remission, whereas CD8 T cells did not show any significant changes.

Conclusion: Plasma cell counts are increased in patients with active GPA which implies a role for plasma cell mediated effects in active GPA. This is probably due to B cell hyperactivity in GPA. Presumably, their main role is the production of autoantibodies, but also cytokine production. Independent of their direct contribution to the disease, they may serve as a biomarker of disease activity as they highly correlate with the BVAS. 


Disclosure:

B. F. Hoyer,
None;

A. Taddeo,
None;

M. Rothkegel,
None;

G. Burmester,

Abbott, BMS, MSD, Pfizer Inc., Roche, UCB,

2,

Abbott, BMS, MSD, Pfizer Inc., Roche, UCB,

5,

Abbott, BMS, MSD, Pfizer Inc., Roche, UCB,

8;

A. H. Radbruch,
None;

F. Hiepe,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-cell-analysis-as-a-biomarker-for-disease-activity-in-patients-with-granulomatosis-with-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology